Big Cypress Acquisition Corp.
BCYPW
NASDAQ Global Select1.10
USD
-0.15
- -
CIK
0001833214
Return %
Stock
S&P500
1Y
- -
18.21
3Y
- -
63.29
5Y
- -
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Samuel J. Reich
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 300 West 41st Street Miami Beach FL United States of America
- IPO Date
- Feb 9, 2021
- CIK
- 0001833214
- Similar Companies
- Business
- Big Cypress Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in 2020 and headquartered in Miami Beach, Florida. The company primarily focuses on acquiring growth-oriented firms in the life sciences sector. Big Cypress Acquisition Corp does not have significant operations of its own but aims to acquire assets and businesses through mergers, capital stock exchanges, stock purchases, reorganizations, or similar business combinations. The company’s most significant recent development is its reverse merger business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company specializing in immunotherapies. The merger, completed in late 2021, resulted in SAB Biotherapeutics becoming a publicly traded company on NASDAQ under the SAB ticker symbol, with Big Cypress Acquisition Corp effectively acquired by SAB Biotherapeutics. SAB Biotherapeutics advances a proprietary DiversitAb™ platform leveraging genetically engineered transchromosomic bovine herds to produce fully human polyclonal antibody therapeutics targeting immune system disorders, cancer, and infectious diseases. This merger fuels SAB Biotherapeutics’ development and commercialization efforts in novel therapeutic areas including immune disorders and infectious diseases. Beyond the merger, Big Cypress Acquisition Corp’s focus on innovative biopharmaceutical firms and growth in the life sciences sector underscores its strategic positioning. The company targets businesses offering novel products or platforms with potential for rapid development and commercialization in health-related markets. In summary, Big Cypress Acquisition Corp serves as a vehicle for life sciences company acquisitions, with its primary recent activity being the major business combination with SAB Biotherapeutics, enabling SAB’s expansion and NASDAQ listing with advanced immunotherapy product offerings. The company operates within the U.S. and targets innovative biopharmaceutical companies for growth and development opportunities.